

Francesco Longo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2961354/publications.pdf>

Version: 2024-02-01

19
papers

658
citations

687363

13
h-index

794594

19
g-index

25
all docs

25
docs citations

25
times ranked

1054
citing authors

#	ARTICLE	IF	CITATIONS
1	LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. <i>Frontiers in Molecular Neuroscience</i> , 2014, 7, 49.	2.9	82
2	Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimer's disease. <i>Science Signaling</i> , 2021, 14, .	3.6	75
3	Age-dependent dopamine transporter dysfunction and Serine129 phospho- α -synuclein overload in G2019S LRRK2 mice. <i>Acta Neuropathologica Communications</i> , 2017, 5, 22.	5.2	73
4	Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice. <i>Science Signaling</i> , 2017, 10, .	3.6	73
5	Cognitive Impairment and Dentate Gyrus Synaptic Dysfunction in Experimental Parkinsonism. <i>Biological Psychiatry</i> , 2014, 75, 701-710.	1.3	56
6	Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. <i>Neurobiology of Disease</i> , 2014, 71, 62-73.	4.4	48
7	Cell-type-specific drug-inducible protein synthesis inhibition demonstrates that memory consolidation requires rapid neuronal translation. <i>Nature Neuroscience</i> , 2020, 23, 281-292.	14.8	40
8	UPF2 leads to degradation of dendritically targeted mRNAs to regulate synaptic plasticity and cognitive function. <i>Molecular Psychiatry</i> , 2020, 25, 3360-3379.	7.9	38
9	Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model. <i>Neuropsychopharmacology</i> , 2019, 44, 324-333.	5.4	37
10	Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. <i>Neurobiology of Disease</i> , 2016, 89, 55-64.	4.4	24
11	Cell-type-specific disruption of PERK-eIF2 α signaling in dopaminergic neurons alters motor and cognitive function. <i>Molecular Psychiatry</i> , 2021, 26, 6427-6450.	7.9	18
12	Protein Kinase C δ : a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain. <i>Neuropsychopharmacology</i> , 2017, 42, 1491-1501.	5.4	15
13	Reciprocal control of translation and transcription in autism spectrum disorder. <i>EMBO Reports</i> , 2021, 22, e52110.	4.5	15
14	Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrcortical synaptosomes. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00484.	2.4	14
15	Genetic removal of p70 S6K1 corrects coding sequence length-dependent alterations in mRNA translation in fragile X syndrome mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	14
16	Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity. <i>Materials Science and Engineering C</i> , 2015, 48, 294-300.	7.3	11
17	L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter. <i>Brain Research</i> , 2021, 1768, 147583.	2.2	9
18	Inositol polyphosphate multikinase mediates extinction of fear memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2707-2712.	7.1	7

#	ARTICLE	IF	CITATIONS
19	Key role for hypothalamic interleukin-6 in food-motivated behavior and body weight regulation. Psychoneuroendocrinology, 2021, 131, 105284.	2.7	6